Navigation Links
Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market

EXTON, Pa., Aug. 24 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrends®: Vascular Access report. This report is based on online survey results from over 150 physicians (general nephrologists, surgeons, interventional radiologists and interventional nephrologists). It provides an in-depth view of the dialysis vascular access market and current practice patterns related to both vascular access placement and maintenance.  

The report explores the roles of various physicians related to vascular access, reasons for choice of different access options and barriers to fistula use. It also looks at the type and frequency of interventions being performed and impact on missed dialysis sessions. The report also reviews controversies and challenges in vascular access, physician perceptions and expectations about the future of the dialysis vascular access market including the impact of bundling and projected use of fistulas, grafts and catheters in both incident and prevalent dialysis patients. Physician awareness, perceptions and use of the latest access option, Hemosphere's HeRO device, is also included. Thought leaders, as well as companies / representatives that are active in the vascular access field, are identified.  

"This unique report clearly demonstrates many of the challenges that continue to exist regarding the improvement of incident and prevalent arteriovenous fistula rates," said Dr. Jay Wish, clinical consultant at the Fistula First Breakthrough Initiative. "Moreover, it reveals a disconnect among the expectations of nephrologists, surgeons and interventionalists that may be a barrier to optimal fistula use. It is hoped that continued research into some of these areas of controversy will promote the development of more evidence-based guidance regarding vascular access selection, timing, monitoring, and the use of newer agents to increase short and long-term patency."

On the horizon, there are a number of products in development that may improve fistula maturation rates and / or improve vascular access patency. Physicians in this report provide insight into what they consider to be a clinically significant reduction in clot events and provide input on the perceived value, advantages and disadvantages of Ark's Trinam, Cytografts' Lifeline, Pervasis' Vascugel, and Proteon's PRT-201, all of which are in development and profiled in the report.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks of their respective holders.BioTrends Research Group, Inc.Sharon  Decision Resources, Inc.Christopher Comfort781-296-2597

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
4. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
5. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
6. DaVita Abstracts Highlight Latest Research Developments at Annual Dialysis Conference
7. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
8. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
9. Latest Content Release for The T SystemEV EDIS Supports Clinicians in Providing Quality Care for H1N1 Patients
10. November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers
11. Leading Event for People With Disabilities on November 6-8 Features Latest Technologies, Products, Services, and More
Post Your Comments:
(Date:11/27/2015)... Niederlande, November 27, 2015 ... bei fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
(Date:11/26/2015)... , Nederland, November 26, 2015 /PRNewswire/ ... --> Een nieuwe aanpak combineert immunotherapie ... gevorderde kanker. ) ... -->      (Photo: ... het Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/27/2015)... California (PRWEB) , ... November 27, 2015 , ... Avid ... Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most ... the Canterbury House at the University of Michigan in Ann Arbor. The According to ...
(Date:11/26/2015)... Marne, MI (PRWEB) , ... November 26, 2015 ... ... center for substance abuse located in central Michigan, have come together on Thanksgiving ... a specially produced video, available for viewing on the Serenity Point YouTube channel, ...
(Date:11/26/2015)... Cambridge, ON (PRWEB) , ... November 26, 2015 ... ... availability of a real-time eReferral system for diagnostic imaging in the Waterloo region. ... mammography, BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied ... the need to integrate dose form selection in early phase drug development. The ... organization supporting and bringing together the UK’s emerging life sciences companies, corporate partners, ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
Breaking Medicine News(10 mins):